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The two products of the KRAS locus, K-Ras4A and K-Ras4B, are
encoded by alternative fourth exons and therefore, possess distinct
membrane-targeting sequences. The common activating mutations
occur in exons 1 or 2 and therefore, render both splice variants
oncogenic. K-Ras4A has been understudied, because it has been
considered a minor splice variant. By priming off of the splice junc-
tion, we developed a quantitative RT-PCR assay for K-Ras4A and
K-Ras4B message capable of measuring absolute amounts of the
two transcripts. We found that K-Ras4A was widely expressed in
30 of 30 human cancer cell lines and amounts equal to K-Ras4B in 17
human colorectal tumors. Using splice variant-specific antibodies,
we detected K-Ras4A protein in several tumor cell lines at a level
equal to or greater than that of K-Ras4B. In addition to the CAAX
motif, the C terminus of K-Ras4A contains a site of palmitoylation as
well as a bipartite polybasic region. Although both were required
for maximal efficiency, each of these could independently deliver
K-Ras4A to the plasma membrane. Thus, among four Ras proteins,
K-Ras4A is unique in possessing a dual membrane-targeting motif.
We also found that, unlike K-Ras4B, K-Ras4A does not bind to the
cytosolic chaperone δ-subunit of cGMP phosphodiesterase type 6
(PDE6δ). We conclude that efforts to develop anti–K-Ras drugs that
interfere with membrane trafficking will have to take into account
the distinct modes of targeting of the two K-Ras splice variants.
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Ras genes are the most frequently mutated oncogenes in hu-man cancer (1) and therefore, considered among the most
important targets for anticancer therapy. The Ras genes encode
small GTPases that control cellular pathways that signal for growth,
proliferation, and differentiation. Mammalian genomes harbor three
Ras genes (HRAS, NRAS, and KRAS) that give rise to four proteins.
The 21-kDa gene products of Ras loci share nearly identical se-
quence homology through the first 165 of 188 to 189 aa. The G
domain formed by these 165 aa is the catalytic and switching portion
of the protein that binds GDP/GTP and associates with effec-
tors, exchange factors, and GTPase-activating proteins (GAPs) (2).
Where the Ras isoforms diverge is in their 24 C-terminal aa, which
contain the targeting information for the membrane localization that
is necessary for Ras function (3). This hypervariable region (HVR)
includes a C-terminal CAAX sequence, which is modified post-
translationally in three steps: farnesylation, AAX proteolysis, and
carboxyl methylation of the resulting C-terminal prenylcysteine (4).
Whereas CAAX processing is required for membrane associ-
ation, it is insufficient for targeting Ras proteins to the plasma
membrane (PM) (5). A second signal upstream of the CAAX
motif directs Ras proteins to the PM (6). In N-Ras and H-Ras,
the second signal consists of one or two cysteine residues that
serve as sites of palmitoylation. K-Ras4B lacks palmitoylation
but instead, contains a series of lysines that constitutes a poly-
basic region (PBR) capable of interacting, without additional
modification, with the inner leaflet of the PM through an elec-
trostatic interaction. Unlike CAAX processing, the second sig-
nals are reversible, because the palmitoyl thioester modifications
of N-Ras and H-Ras are labile and because the charge of the
PBR of K-Ras4B can be diminished by phosphorylation of a
serine interposed within the sequence (7).
The KRAS gene is unique among Ras genes in that it encodes
two gene products by alternative splicing. The two transcripts
differ by use of two alternative fourth exons and therefore, are
designated K-Ras4A and K-Ras4B. The alternative fourth exons
encode the HVRs of the proteins that are responsible for mem-
brane targeting. Whereas K-Ras4B lacks a site of palmitoylation,
K-Ras4A is palmitoylated (8). K-Ras4A mRNA is expressed early
in embryogenesis and differentially expressed in adult tissues (9).
In humans, K-Ras4A is reported to be expressed in the gastroin-
testinal tract and to a lesser degree, kidney, lung, and other tissues
of endodermal origin as well as some mesodermal derivatives but
not at all in nervous system or skeletal muscle (10). Although the
KRAS gene locus is essential for mouse embryonic development,
expression of K-Ras4A is not essential, because targeted KO of
exon 4A in mice resulted in no impairment in survival, growth, or
fertility (11). Whether K-Ras4A can substitute for K-Ras4B in
development has not been tested.
The K-Ras4A splice variant is conserved in eukaryotes (Fig.
S1). The evolution of two splice variants of KRAS and the
differential expression of the two transcripts suggest distinct
functions. However, no unambiguous evidence for differential
function has been reported. It is clear that activated K-Ras4A is
capable of transforming cells. Notably, K-Ras4A was the first
splice variant discovered by virtue of it being the transforming
gene carried by the Kirsten murine sarcoma virus (12). Mutated
K-Ras4A has been shown to activate Raf-1 and signal through
the MAPK pathway much more efficiently than oncogenic
H-Ras and N-Ras, and the ability of oncogenic K-Ras4A to induce
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formation of transformed foci and enable anchorage-inde-
pendent growth is significantly greater than that of oncogenic
K-Ras4B expressed at the same level (13). A recent study suggested
that the presence of oncogenic K-Ras4A was necessary to initiate
tumor formation and growth in a mouse model of induced lung
carcinogenesis through KRAS mutation (14). Importantly, because
the mutations found in human cancer that render KRAS constitu-
tively active are located in exons 1 and 2, both splice variants
expressed from a mutated allele will encode oncogenic proteins.
Because mRNA levels of K-Ras4A have been reported to be
lower than those of K-Ras4B (9, 10, 15), the former has been
considered the minor splice variant of the KRAS locus and largely
ignored in the vast literature on K-Ras.
In this study, we develop superior tools to detect expression of
K-Ras4A at the message and protein levels, revisit the question
of relative expression of the K-Ras splice variants in human
cancer, and conclude that a significant amount of K-Ras4A is
expressed in colorectal carcinoma. We also show that K-Ras4A
is unique among Ras isoforms in that it contains two targeting
signals in its HVR, which act redundantly to direct K-Ras4A to
the PM, where it is able to signal.
Results
K-Ras4A Is Expressed in Human Cancer. The only difference in
K-Ras4A vs. K-Ras4B mRNA is the presence or absence of exon
4A (Fig. 1A). Previous studies of the relative abundance of the two
transcripts used primers that initiate in exons 1 (forward) and 4B
(reverse), such that an amplification product was obtained with
either transcript, and the splice variant assignment was made
based on the size of the product (10). We found that, using such
primers and plasmid-encoded cDNAs as templates, the amplifi-
cation efficiency varied dramatically depending on the presence or
absence of exon 4A, such that the relative abundance of size-
defined amplification products does not accurately reflect the rel-
ative abundance of the two transcripts. Accordingly, we developed
a reverse primer that initiates across the exon 3/4B splice junction,
such that a product is observed only when the template lacks exon
4A (Fig. 1A). A second reverse primer in the 4A exon produced
a 4A-specific product. Using cDNA of each K-Ras splice variant
cloned into a pEGFP vector backbone, we generated standard
curves for each quantitative PCR (qPCR) reaction, such that we
were able to determine the absolute concentrations of each tem-
plate as a function of the amplification products (Fig. S2). cDNAs
from a variety of human cancer cell lines derived from different
tumors with or without KRAS mutations were used to study
the relative abundance of K-Ras4A and K-Ras4B transcripts.
Although K-Ras4B message was more abundant overall, the
K-Ras4A transcript was expressed in every cell line examined (Fig.
1B), with particular prominence in cell lines derived from colon
carcinoma and melanoma. K-Ras4A accounted for 10–50% of
total KRAS transcripts, levels significantly higher than previously
reported (10, 15, 16). The relative abundance of the two tran-
scripts did not seem to correlate with K-Ras mutations. To better
determine if the KRAS mutational status affects splicing, we ex-
amined isogenic cell line pairs for the colon cancer cell lines
DLD-1 and HCT116 (17). We did not observe any difference in
the relative abundance of the two mRNAs among cells that harbor
WT vs. mutated KRAS alleles (Fig. S3).
To confirm that our observations with established cancer cell
lines, which are susceptible to genetic drift in culture, reflected
the status of primary human tumors, we examined by RT-qPCR
fresh frozen tissue from 17 colorectal adenocarcinomas. Strik-
ingly, the relative abundance of K-Ras4A and K-Ras4B mRNA
was more equal than that observed in cell lines. Indeed, over the
entire set of samples, the relative abundance of the two tran-
scripts was equal (Fig. 1C).
To determine if our RT-qPCR findings translate into protein
expression, we developed a rabbit polyclonal antibody specific
for K-Ras4A (Fig. 1D). Using this anti–K-Ras4A antibody, we
were able to detect the presence of K-Ras4A protein in cell lines
derived from colorectal and bladder tumors (Fig. 1 D and E).
Using isoform-specific anti-Ras antibodies (Fig. S4) and stan-
dard curves generated with bacterially expressed 6xHis-Ras
proteins (Fig. S5), we determined that the cellular contents of
K-Ras4A, K-Ras4B, N-Ras, and H-Ras in HT29 cells were 2.6,
1.2, 2.8, and 0.7 ng/106 cells, respectively (Fig. 1E). Thus, K-
Ras4A is relatively well-expressed in human colorectal cancer
cell lines and tissues and perhaps, other human cancers.
K-Ras4A Uses Two Targeting Motifs to Traffic to the PM. Like N-Ras
and H-Ras, the HVR of K-Ras4A contains a cysteine that has
been shown to be palmitoylated (8). Indeed, the HVR of
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Fig. 1. K-Ras4A is expressed in human cancer. (A, Upper) Schematic of
K-Ras4A and K-Ras4B mRNA sequences with locations of primer pairs used for
RT-PCR indicated. Reverse primers were designed to prime in exon 4A or the
exon 3/4B splice. (A, Lower) Representative agarose gel showing RT-PCR
products using 4A- or 4B-specific primer pairs and the indicated cDNA tem-
plate. (B and C) Quantification of K-Ras isoform transcripts. cDNA from total
RNA extracts was generated from (B) indicated cancer cell lines or (C) fresh
frozen colorectal tumors, and qPCR was performed using the primer pairs
indicated in A. Results are graphed as percentage of K-Ras isoform transcript
relative to total K-Ras mRNA. In B, asterisks indicate cell lines with mutated
KRAS. In B and C, the data shown are the means of two to three independent
determinations (error bars representing SD are shown when n = 3). (D, Upper)
Validation of the specificity of an anti–K-Ras4A antibody. (D, Lower) Lysates
from indicated cancer cell lines (HCT116, HT29, and CaCo-2 from colorectal
carcinoma and T24, J82, and 5637 cells from urothelial carcinoma) were
immunoprecipitated for Ras and immunoblotted using the K-Ras4A–specific or
antitotal K-Ras antibodies. (E) Lysates of 107 HT29 cells were immunoprecipi-
tated for total Ras, and the indicated amounts of eluate (total volume = 133
μL) were immunoblotted for the indicated Ras isoforms alongside a standard
curve generated with bacterially expressed 6xHis-tagged Ras proteins.
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N-Ras and H-Ras as well as other palmitoylated small GTPases
are expressed on both the PM and Golgi apparatus (18). In
striking contrast, when we imaged live cells expressing K-Ras4A
fused to GFP, we found that GFP-K-Ras4A localized exclusively
to the PM (Fig. 2B). Because cysteine 180 is the only cysteine in
the K-Ras4A HVR apart from the farnesylated CAAX cysteine
and because Laude and Prior (8) found [3H]palmitate incor-
poration into GFP extended with the HVR only, one site of
K-Ras4A palmitoylation is thought to be cysteine 180. To con-
firm that palmitoylation of cysteine 180 is required for K-Ras4A
membrane association, we mutated the presumed palmitate ac-
ceptor site to serine. GFP-K-Ras4A180S localized extensively to
internal membranes, indicating that palmitoylation is, indeed,
required for efficient targeting of K-Ras4A to the PM (Fig. 2B).
However, a portion of GFP-K-Ras4A180S was clearly observed
at the PM, which is in stark contrast to GFP-N-Ras181S (Fig.
2B). Treatment of cells expressing GFP-K-Ras4A with 2-bro-
mopalmitate, an inhibitor of palmitoylation, led to increased
expression on endomembrane but failed to block expression on
the PM. In contrast, GFP-N-Ras was blocked completely from
the PM under the same conditions (Fig. 2C). Thus, despite a role
for palmitoylation in K-Ras4A membrane trafficking, another
targeting signal in K-Ras4A is able to direct it to the PM in the
absence of palmitoylation.
Analysis of the C-terminal sequence of K-Ras4A revealed two
clusters of positively charged residues (PB1 and PB2), suggesting
that, like K-Ras4B, K-Ras4A may contain PBRs active in
membrane targeting (Fig. 3A). The observation that the steady-
state localization of GFP-K-Ras4A was identical to that of
K-Ras4B (Fig. 3B) but differed from that of N-Ras (Fig. 2B) and
H-Ras (5) is consistent with a functional PBR. Indeed, Laude and
Prior (8) previously reported that PB2 stabilizes the interaction
of the palmitate on K-Ras4A with the PM. We hypothesized
that, when palmitoylation of K-Ras4A was absent, PB1 and/or
PB2 are sufficient to direct K-Ras4A to the PM. To test this hy-
pothesis, we mutated the positively charged residues in each PBR
to electrostatically neutral glutamines either singly or combined.
Removal of either PBR alone (ΔPB1 or ΔPB2) did not signifi-
cantly affect K-Ras4A localization (Fig. 3B). However, removal
of both PBRs (ΔPB1+2) changed the steady-state distribution
of K-Ras4A to the PM and Golgi apparatus (Fig. 3B and Fig. S6).
Thus, GFP-K-Ras4A(ΔPB1+2) was expressed in a pattern iden-
tical to that of GFP-N-Ras and GFP-H-Ras, the Ras isoforms that
depend absolutely on palmitoylation for PM expression.
Next, we removed the site of palmitoylation combined with
a PBR, so that only one PBR remained. The loss of both PB1
and palmitoylation resembled the C180S mutant alone, albeit
with diminished but not absent PM localization (Fig. 3C). In
contrast, loss of PB2 and palmitoylation completely removed
K-Ras4A from the PM and resulted in localization exclusively to
endomembrane and cytosol, confirming that both palmitoylation
and PB2 are required for efficient targeting to the PM.
To rule out the possibility that one or both PBRs are required
for palmitoylation of K-Ras4A, we performed metabolic labeling
with [3H]palmitic acid. We found that K-Ras4A lacking cysteine
180 failed to incorporate any [3H]palmitic acid (Fig. S7), thus
showing for the first time, to our knowledge, that cysteine 180 is
the only site of palmitoylation in K-Ras4A. Mutation of the
PBRs, either singly or together, did not affect the steady-state
incorporation of palmitate (Fig. S7). Thus, the PBRs do not
affect the efficiency of palmitoylation of K-Ras4A expressed by
transfection, suggesting that the PBRs have an alternative direct
role in the membrane targeting of the protein.
K-Ras4B but Not K-Ras4A Binds the δ-Subunit of cGMP Phosphodiesterase
Type 6. In addition to vesicular transport, the trafficking of Ras

































Fig. 2. K-Ras4A is targeted to the PM, even in the absence of palmitoyla-
tion. (A) Sequences of the C-terminal HVRs of four Ras proteins. The farne-
sylated cysteine of the CAAX motif is indicated in yellow, whereas the
cysteines serving as sites of palmitoylation are in green. For K-Ras4B, the
polybasic domain is in red, with blue indicating the site of phosphorylation.
(B) HEK293 cells were transfected with the indicated constructs and imaged
live by confocal microscopy. (C) HEK293 cells were transfected with GFP-K-
Ras4A or GFP-N-Ras and treated with 2-bromopalmitate (2-BP; 50 μM) or
vehicle (DMSO) for 3 h before imaging live by confocal microscopy. All
images are representative of the indicated percentage of >50 live fluores-






















Fig. 3. Polybasic domains contribute to K-Ras4A PM localization. (A)
Sequences of the K-Ras4B and K-Ras4A C-terminal HVRs with PBRs (PB1 and
PB2) underlined. Features are indicated as described in Fig. 2A. (B and C)
HEK293 cells were transfected with the indicated constructs and imaged live
by confocal microscopy. ΔPB1 and ΔPB2 mutations indicate 167–170 QLQQ
and 182–185 QIQQ substitutions, respectively. ΔPB1+2 indicates combined
substitutions at both PBRs. All images are representative of the indicated
percentage of >50 live fluorescent cells examined. (Scale bar: 10 μm.)








of lipidated, hydrophobic molecules across the aqueous environ-
ment of the cytosol and therefore, requires cytosolic chaperones
capable of shielding their lipid moieties. One of these is the
δ-subunit of cGMP phosphodiesterase type 6 (PDE6δ) (19). We
confirmed (Fig. 4) that K-Ras4B and N-Ras but not H-Ras can be
extracted from membranes by overexpression of PDE6δ (19, 20).
Strikingly, PDE6δ did not function as a cytosolic chaperone for
K-Ras4A (Fig. 4). Thus, despite identical steady-state localizations
at the PM (Fig. 3B), K-Ras4B and K-Ras4A have distinct mech-
anisms of subcellular trafficking.
K-Ras4A Localization Signals Affect Its Downstream Signaling. Dis-
ruption of neither palmitoylation (180S) nor the PBRs (ΔPB1+
2) alone affected the EGF-stimulated GTP loading of K-Ras4A
(Fig. 5A), supporting the observation that either form of second
signal can deliver K-Ras4A to the PM, where it will encounter
the exchange factor SOS. Curiously, when only PB2 was removed
(ΔPB2), GTP loading was diminished by 40% (P < 0.02), and
when PB2 was removed in conjunction with loss of palmitoyla-
tion (ΔPB2+180S), GTP loading was inhibited by 70% (P <
0.005). Thus, PB2 plays a critical role in nucleotide exchange on
K-Ras4A with or without palmitoylation.
The C-terminal mutations did not affect the constitutively
GTP-loaded state of 12V mutations of K-Ras4A (Fig. S8A).
K-Ras4A12V180S was significantly impaired in driving ERK
phosphorylation relative to K-Ras4A12V, although phospho-
ERK levels were higher than controls, indicating diminished but
persistent signaling (Fig. 5B). Mutation of either PBR alone did
not affect phospho-ERK levels, and although mutation of both
PBRs consistently decreased phospho-ERK levels, this difference
was not significant (n = 4) (Fig. 5B). Mutation of either PBR
combined with loss of palmitoylation significantly reduced ERK
phosphorylation to the baseline level found in cells transfected
with an empty vector. These levels were similar to those of
K-Ras4A12V186S that cannot be prenylated (Fig. 5B). These
results were corroborated with assays of anchorage-independent
growth of rodent fibroblasts (Fig. 5C and Fig. S8 B and C). Colony
growth in soft agar was reduced but not eliminated by removal of
either PBR alone (ΔPB1 or ΔPB2) or combined (ΔPB1+2) or
abolition of palmitoylation (180S). In contrast, removal of PB2
and the palmitoylation site resulted in no more colonies than
vector alone. Thus, the ability of K-Ras4A to maximally drive
MAPK signaling and transform cells requires both palmitoylation
and at least one PBR, and removal of one or the other targeting
motifs diminishes but does not abolish activity.
To explore the downstream signaling of K-Ras4A in a more
biologically relevant context, we used PC12 cells, which differ-
entiate in response to expression of activated Ras proteins in the
absence of growth factor stimulation. Expression of GFP-tagged
K-Ras4A12V, N-Ras12D, and H-Ras12V all induced differen-
tiation of PC12 cells as determined by neurite outgrowth,
but when palmitoylation was eliminated by mutation, only
K-Ras4A12V retained the ability to stimulate neurite outgrowth
(Fig. 5D). Thus, K-Ras4A behaves in a manner strikingly dif-
ferent from that of H-Ras and N-Ras with regard to the re-
quirement for palmitoylation. Like elimination of palmitoylation,
loss of the PBRs did not affect the ability for K-Ras4A12V to
induce PC12 cell differentiation (Fig. 5E). The loss of palmi-
toylation in conjunction with PB1 (ΔPB1+180S) reduced the
ability to stimulate neurite outgrowth by 50%, indicating that
PB2 can function in isolation. Strikingly, the combined loss of
palmitoylation and PB2 (ΔPB2+180S) resulted in a K-Ras4A
protein that was totally inactive in stimulating PC12 differenti-
ation, supporting the conclusion that PB2 is essential for
K-Ras4A signaling (Fig. 5E). Interestingly, although the HVR
mutations that completely blocked delivery to the PM also
blocked signaling, there was no one-to-one correlation between
the extent of PM localization and signaling; for example, whereas
ΔPB1 and ΔPB2 localized to the PM to similar extents (Fig. 3B),
12V ΔPB1 was two times as efficient as 12V ΔPB2 in activating
MAPK (Fig. 5A). Nevertheless, taken together, the signaling data
are consistent with the observed localization patterns of K-Ras4A
and support the idea that K-Ras4A contains two independently
acting membrane-targeting signals, either one of which is sufficient
for signal output.
Discussion
Our data reveal expression of K-Ras4A mRNA in all 30 human
cell lines examined. Although K-Ras4B message was present at
higher levels in the majority of these, in 40% of these lines, the
K-Ras4A transcript exceeded 20% of total K-Ras message, and
in several, the mRNA levels for the two splice variants were
relatively equal. More compelling was the analysis of fresh co-
lorectal tumors, where expression levels of the two transcripts
were equal over a panel of 17 samples. It is likely that our results
differ from those previously reported (10, 15, 16), because we
used splice variant-specific RT-qPCR primers and measured
absolute mRNA levels against a standard curve generated with
each experiment. Our results analyzing mRNA were supported
by studies of protein expression. We developed a K-Ras4A–
specific antibody that permitted the first demonstration, to our
knowledge, of K-Ras4A protein in cancer cell lines. Using
standard curves generated with recombinant protein, we were
able to measure the absolute levels of all four Ras proteins in
HT29 colorectal cancer cells that harbor a mutant KRAS gene




















Fig. 4. PDE6δ fails to extract K-Ras4A from membranes. HEK293 cells were
transfected with the indicated GFP-tagged Ras proteins (Right) alone or (Left
and Center) along with mCherry-PDE6δ and imaged live 24 h later. Asterisks
indicate cells in which PDE6δ extracted Ras frommembranes. (Scale bar: 10 μm.)
782 | www.pnas.org/cgi/doi/10.1073/pnas.1412811112 Tsai et al.
N-Ras and in excess of K-Ras4B and H-Ras. Our data show that
K-Ras4A is expressed in human cancer cells and thereby, dispel
the widely held notion that the K-Ras4A splice variant does not
contribute to oncogenesis or tumor maintenance when the KRAS
gene sustains an activating mutation.
The conservation of the KRAS 4A exon through evolution and
the expression of K-Ras4A in human tissues suggest non-
redundant functions for the two splice variants; however, the
evidence for distinct activities is limited and often contradictory.
Both splice variants of K-Ras are highly transforming in standard
assays using rodent fibroblasts, and in one study, K-Ras4A was
more active than K-Ras4B (13). Perhaps the most compelling
argument for a role for K-Ras4A in oncogenesis is the fact that
the transforming gene carried by the Kirsten rat sarcoma virus is
the K-Ras4A cDNA (12).
Whereas the NRAS and HRAS loci are dispensable for mouse
development, the KRAS locus is essential (21–23). However,
mice homozygous for the HRAS cDNA knocked into the KRAS
locus are viable (24), suggesting that the essentiality of the KRAS
locus is, at least in part, because of gene expression patterns
rather than differential function of the gene products. Exon 4A is
also dispensable with regard to mouse development (11), but the
reciprocal experiment (the viability of a mouse expressing ex-
clusively K-Ras4A from the KRAS locus) has not been reported.
Most evidence for an independent function of K-Ras4A has
been deduced from the exon 4A KO mouse. Cells isolated from
this mouse exhibited impaired apoptosis in vitro in response to
etoposide, like the gastrointestinal tract of these mice when
treated with etoposide by i.p. injection (25). Similarly, when
colonic adenomas were induced in these mice by treatment with
1,2-dimethylhydrazine, mice lacking K-Ras4A had an increase in
number and size of colonic adenomas that revealed increased
markers of proliferation and decreased markers of apoptosis
(26), suggesting that, despite the highly counterintuitive nature
of these findings, WT K-Ras4A can behave like a tumor sup-
pressor. However, a similar study using a mouse genetic model to
induce colon carcinomas showed no such effect of K-Ras4A
deficiency (27). Another study using a different mouse transgenic
at the KRAS locus revealed a role for K-Ras4A in tumorigenesis:
when the cDNA sequence of K-Ras4B was knocked into the
KRAS locus, such that only K-Ras4B could be expressed (des-
ignated KRASKI), homozygous KRASKI mice were resistant to
urethane-induced lung carcinogenesis (14). However, the same
study called into question the protumor effects of WT K-Ras4A
by showing that, when the KRASKI allele was heterozygous with
the KRASLA2 allele that spontaneously recombines to generate
oncogenic K-Ras, more lung tumors developed in KRASKI/LA2
than KRASwt/LA2 mice, consistent with a tumor suppressor effect
of WT K-Ras4A (14). Thus, the literature on K-Ras4A–deficient
mice provides little clarity and no mechanistic understanding of
any biological differences that may distinguish the two highly
conserved splice variants of the KRAS locus.
Because the alternative fourth exons encode the membrane-
targeting HVRs of the KRAS gene products, we studied the dif-
ferential subcellular trafficking of the two proteins. We and others
have established that the membrane trafficking of N-Ras and
H-Ras, which are palmitoylated, differs substantially from that of
K-Ras4B, in that N-Ras and H-Ras access the PM through the
cytoplasmic surface of the Golgi apparatus, whereas K-Ras4B
does not associate with the Golgi (5). The protein palmitoylacyl-
transferase that modifies N-Ras and H-Ras, DHHC9/GCP16,
resides on the Golgi (28), and these Ras isoforms engage in a cycle
of palmitoylation/depalmitoylation that takes them to and from
the PM (29–31). At steady state, GFP-N-Ras and GFP-H-Ras can






Fig. 5. Dual membrane-targeting signals support
K-Ras4A signaling. (A) HeLa cells expressing the in-
dicated GFP-K-Ras4A constructs were serum-starved
overnight and then stimulated with EGF (10 ng/mL)
for 3 min. GTP-bound Ras was affinity-purified from
cell lysates with GST–Ras binding domain (RBD). Ras
was detected by immunoblot with a pan-Ras anti-
body from both GST-RBD pull downs and lysates.
Lower shows quantification of GTP loading, with
results presented as fold change in GTP-bound K-
Ras4A normalized to expression. Values are mean ±
SEM (n = 5). (B) Lysates of HeLa cells expressing the
indicated constitutively active GFP-K-Ras4A12V con-
structs were immunoblotted for phospho-ERK, total
ERK, and Ras. Lower shows quantification of phos-
pho-ERK presented as a ratio to total ERK normalized
to GFP-Kras4A expression. Values are mean ± SEM
(n = 4). (C) Anchorage-independent growth of NIH
3T3 fibroblasts stably expressing the indicated con-
structs. Results are shown as the percentages of cells
that form colonies and plotted as mean ± SEM (n = 4).
(D) PC12 cells were transfected with the indicated
GFP-Ras constructs, with + palm indicating the palmi-
toylated form and − palm indicating palmitoylation-
deficient mutants 180S, 181S, or 181,4SS for K-Ras4A,
N-Ras, or H-Ras, respectively. After 3 d, GFP-positive
cells were scored for neurites with lengths ≥1.5 times
the diameter of the cell soma. Data plotted are per-
centages of cells with neurites (mean ± SEM; n = 3).
(E) PC12 cells were transfected with the indicated
GFP-K-Ras4A constructs and scored for neurite pro-
cesses as in C. *P = 0.01; **P = 0.001 (Student’s t test).








In contrast, we observed no GFP-K-Ras4A on the Golgi arguing
for alternative trafficking.
Laude and Prior (8) observed that the HVRs of each of four
Ras isoforms begin with a short PBR and that K-Ras4A has
a second short PBR immediately after palmitoylated cysteine
180. We designated these PBRs PB1 and PB2, respectively. We
found that substitution of the basic residues in PB1+2 with
glutamine generated a K-Ras4A mutant that localized on the
PM and Golgi in a manner indistinguishable from that of N-Ras.
Conversely, although elimination of the palmitoylation site
resulted in mislocalization of GFP-K-Ras4A to internal mem-
branes, this mutant was capable of trafficking to the PM, unlike
palmitoylation-deficient N-Ras. Thus, K-Ras4A is unique among
Ras isoforms in possessing a hybrid membrane-targeting se-
quence that contains both functional PBRs and a site of palmi-
toylation. Importantly, either motif acting alone is sufficient to
deliver K-Ras4A to the PM. Palmitoylation of K-Ras4A without
any evidence of accumulation on the Golgi suggests that a PM
resident palmitoylacyltransferase may modify this protein rather
than DHHC9/GCP16. Another striking and unexpected finding
was that, whereas PDE6δ could extract K-Ras4B from mem-
branes, it did not affect the localization of K-Ras4A, highlighting
the significant differences in their subcellular trafficking. The
results reported here require that the comprehensive scheme of
the subcellular trafficking of Ras proteins (32) be amended to
include a third hybrid pathway used by K-Ras4A (Fig. S9).
Among the most attractive approaches to anti-Ras therapy are
those that interfere with membrane targeting. Our data suggest
that K-Ras4A plays a significant role in K-Ras–driven tumors
and that the mechanism through which K-Ras4A gains access to
the PM is distinct from that of K-Ras4B. Accordingly, the search
for therapies designed to interfere with oncogenic K-Ras by
limiting its access to the PM will have to take into account the
two distinct mechanisms of K-Ras trafficking.
Materials and Methods
qPCR. Cultured human cancer cell lines or fresh frozen colon tumor samples
(acquired through the Massachusetts General Hospital Tissue Repository)
were collected, and RNA was isolated using the RNeasy Plus Mini Kit
(QIAGEN). Reverse transcription was performed on 2–5 mg total RNA using
the SuperScript III First-Strand Synthesis System (Invitrogen); 2% of the re-
verse transcription product was used for real-time PCR using Maxima SYBR
Green qPCR Master Mix (Thermo Scientific) and an MyiQ Thermal Cycler (Bio-
Rad) with primers designed to produce amplicons within K-Ras4A and K-
Ras4B. Results were normalized to a standard curve generated from a di-
lution series of GFP-K-Ras4A and GFP-K-Ras4B plasmid DNA included in each
set of real-time PCR reaction as well as 18S or β-actin cDNA.
Primer sequences are as follows: for total K-Ras (X3), forward: 5′-tacag-
tgcaatgagggacca-3′, reverse: 5′-tcctgagcctgttttgtgtct-3′; for K-Ras4A (X4A;
4A), forward: 5′-agacacaaaacaggctcagga-3′, reverse: 5′-ttcacacagccaggagtc-
ttt-3′; for K-Ras4B (X4B), forward: 5′-agacacaaaacaggctcagga-3′, reverse: 5′-tc-
ttctttttaccatctttgctca-3′; for K-Ras4B (4B), forward: 5′-gactggggagggctttcttt-
3′, reverse: 5′-gcatcatcaacaccctgtct-3′; for 18S RNA, forward: 5′-ggacacgga-
caggattgaca-3′, reverse: 5′-acccacggaatcgagaaaga-3′; for β-actin, forward:
5′-ggggtgttgaaggtctcaaa-3′, reverse: 5′-ggcatcctcaccctgaagta-3′.
Antibody Development. Custom rabbit polyclonal antibodies were developed
by Bio-Synthesis, Inc., including custom peptide synthesis and conjugation.
Peptide sequences of epitopes are as follows: for K-Ras4A, 161-REIRQYRL-
KKISKEEKTPGC-180; for K-Ras4B, 166-HKEKMSKDGKKKKKKSKTKC-186.
Confocal Microscopy. Live cells were seeded in 35-mm dishes containing no.
0 glass coverslips over 15-mm cutouts (MatTek) and transfected with the
relevant constructs. For pharmacological treatment, 2-bromopalmitate was
used at 50 μM for 3 h. Cells were imaged with a Zeiss 510 laser-scanning
confocal microscope (Carl Zeiss MicroImaging, Inc.) using a 63×, N.A. 1.4
objective and a humidified metabolic chamber maintained at 37 °C and 5%
CO2 (Pecon GmbH). Images were processed with Adobe Photoshop CS6.
Additional methods can be found in SI Materials and Methods.
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